We aim to utilize our growing international network to more efficiently develop diagnostic and therapeutic technologies for life-threatening disease
Our Executive Team
History of Coretag
In 2011 Coretag initiated contract research in Leiden University Medical Center (LUMC) in the Netherlands with a catalogue of proprietary cyanines. During this research some of the tested cyanines appeared to bind to necrotic cells.
After additional testing Coretag revealed that the cyanine binds to the proteins which form the cytoskeleton of the cell. Because this proteins only become available in the human body in case the cell has lost its membrane integrity.This moiety provides an selective probe for targeting necrotic cells.
To be able to visualize necrosis on full body scans, Coretag linked a chelator (DOTA) to the cyanine with a PEG-linker. This means that we can now label the probe with radiolabels for detecting and quantify necrosis with an MRI, PET and SPECT scan, but also label it for radio- and hyperthermic therapy which operates from the core of the aggressively growing tumor or metastase.
After this discovery, Coretag patented this invention and initiated a program of additional testing and pre-clinical trials. During the last seven years Coretag tested the platform technology for binding and targeting necrosis in several hospitals and research centers in the Netherlands, Germany, Geneva and Canada. Based on this pre-clinical trials Coretag developed a pipeline of promising applications for diagnostics and therapeutic treatments.
The technology platform of Coretag provides opportunities for the development of various radioligand therapeutics. However Coretag is first focusing on the development and clinical introduction of NC-Scan. This is a radioligand diagnostic for determining the efficacy of the treatment of a solid tumors.
Effect of PLGA NP size on efficiency to target traumatic brain injury Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models The necrosis-avid small molecule HQ4-DTPA as a multimodal imaging agent for monitoring radiation therapyinduced tumor cell death. Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging Targeted nanoparticles for the non-invasive detection of traumatic brain injury by optical imaging and fluorine magnetic resonance imaging Avenues to molecular imaging of dyingcells: Focus on cancer Multimodal image-guided interventions using oncological biomarkers